1890 related articles for article (PubMed ID: 9506190)
21. The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents.
Rosak C
J Diabetes Complications; 2002; 16(1):123-32. PubMed ID: 11872380
[TBL] [Abstract][Full Text] [Related]
22. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).
Wolffenbuttel BH; van Haeften TW
Drugs; 1995 Aug; 50(2):263-88. PubMed ID: 8521759
[TBL] [Abstract][Full Text] [Related]
23. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus.
Turner R; Cull C; Holman R
Ann Intern Med; 1996 Jan; 124(1 Pt 2):136-45. PubMed ID: 8554206
[TBL] [Abstract][Full Text] [Related]
24. Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategies.
Giorgino F; Laviola L; Leonardini A
Diabetes Res Clin Pract; 2005 Jun; 68 Suppl1():S22-9. PubMed ID: 15955371
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular manifestations of insulin resistance.
Chahwala V; Arora R
Am J Ther; 2009; 16(5):e14-28. PubMed ID: 19114874
[TBL] [Abstract][Full Text] [Related]
26. Focus on insulin resistance in type 2 diabetes: therapeutic implications.
Reusch JE
Diabetes Educ; 1998; 24(2):188-93. PubMed ID: 9555358
[TBL] [Abstract][Full Text] [Related]
27. [Repaglinide in combination therapy in type 2 diabetes].
Moses R
Diabetes Metab; 1999 Dec; 25 Suppl 7():26-7. PubMed ID: 10746009
[TBL] [Abstract][Full Text] [Related]
28. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.
Vinik A
Clin Ther; 2007; 29 Spec No():1236-53. PubMed ID: 18046925
[TBL] [Abstract][Full Text] [Related]
29. [A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus].
Ozawa H; Murai Y; Ozawa T
Yakushigaku Zasshi; 2003; 38(1):11-27. PubMed ID: 14570054
[TBL] [Abstract][Full Text] [Related]
30. Current treatment approaches to type 2 diabetes mellitus: successes and shortcomings.
Collins FM
Am J Manag Care; 2002 Oct; 8(16 Suppl):S460-71. PubMed ID: 12408409
[TBL] [Abstract][Full Text] [Related]
31. Managing obesity and glycemic control in insulin-using patients: clinical relevance and practice recommendations.
Gottesman I
Diabetes Res Clin Pract; 2004 Sep; 65 Suppl 1():S17-22. PubMed ID: 15315866
[TBL] [Abstract][Full Text] [Related]
32. Glucose supply and insulin demand dynamics of antidiabetic agents.
Monte SV; Schentag JJ; Adelman MH; Paladino JA
J Diabetes Sci Technol; 2010 Mar; 4(2):365-81. PubMed ID: 20307399
[TBL] [Abstract][Full Text] [Related]
33. Potential new treatments for type 2 diabetes.
Bailey CJ
Trends Pharmacol Sci; 2000 Jul; 21(7):259-65. PubMed ID: 10871894
[TBL] [Abstract][Full Text] [Related]
34. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions.
Dagogo-Jack S; Santiago JV
Arch Intern Med; 1997 Sep; 157(16):1802-17. PubMed ID: 9290539
[TBL] [Abstract][Full Text] [Related]
35. [Progress in the prevention of type 2 diabetes].
Schernthaner G
Wien Klin Wochenschr; 2003 Nov; 115(21-22):745-57. PubMed ID: 14743578
[TBL] [Abstract][Full Text] [Related]
36. EADSG Guidelines: Insulin Therapy in Diabetes.
Silver B; Ramaiya K; Andrew SB; Fredrick O; Bajaj S; Kalra S; Charlotte BM; Claudine K; Makhoba A
Diabetes Ther; 2018 Apr; 9(2):449-492. PubMed ID: 29508275
[TBL] [Abstract][Full Text] [Related]
37. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
[TBL] [Abstract][Full Text] [Related]
38. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus.
Del Prato S; Tiengo A
Diabetes Metab Res Rev; 2001; 17(3):164-74. PubMed ID: 11424229
[TBL] [Abstract][Full Text] [Related]
39. Optimising therapy for insulin-treated type 2 diabetes mellitus.
Hermann LS
Drugs Aging; 2000 Oct; 17(4):283-94. PubMed ID: 11087006
[TBL] [Abstract][Full Text] [Related]
40. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
Johnson MD; Campbell LK; Campbell RK
Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
